Resources from the same session
1913O - A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Presenter: Patricia Pautier
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1913O
Presenter: Dario Callegaro
Session: Proffered Paper session - Sarcoma
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Sarcoma
Resources:
Webcast
LBA89 - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Presenter: Robin Jones
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA89
Presenter: Sebastian Bauer
Session: Proffered Paper session - Sarcoma
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Sarcoma
Resources:
Webcast
LBA90 - A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415)
Presenter: Viktor Gruenwald
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA91 - TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments
Presenter: Lorenzo D'Ambrosio
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Sarcoma
Resources:
Webcast